Barclays Increases Price Target for Johnson & Johnson Due to Strong Pharma Performance
Barclays raised Johnson & Johnson's (JNJ) price target to $255 from $234, citing strong performance in its pharmaceutical division. The firm reiterated an Equal Weight rating, highlighting J&J's sixth consecutive quarter of double-digit organic growth in pharma and its growth strategy across key therapeutic areas.
Tickers: $JNJ
Topics: Barclays Johnson & Johnson pharma growth price target stock analysis